AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

    NEXT STORY
    Meridian Launches its New Air-Dryable Mix for Crude Blood Samples
    PREV STORY
    Delcath Systems to Participate at Upcoming Virtual Investor Conferences
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

    author_avatar
    NASDAQ Market News

    Inventiva to Participate at the H.C. Wainwright Global Life Sciences Conference

    author_avatar
    NASDAQ Market News

    HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers

    author_avatar
    NASDAQ Market News